Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome

International Journal of Hematology

Volumn 72, Issue 2, 2000, Pages 134-138

  Cazzola, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Cyclosporin a; Desferrioxamine; Erythropoietin; G CSF; Immunosuppressive therapy; Myelodysplastic syndrome; Supportive therapy

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOPOIETIC GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; MYELOABLATIVE AGENT; RADIOPROTECTIVE AGENT;

HUMAN; MYELODYSPLASTIC SYNDROME; REVIEW;

ANTINEOPLASTIC AGENTS; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYELOABLATIVE AGONISTS; MYELODYSPLASTIC SYNDROMES; RADIATION-PROTECTIVE AGENTS;

EID: 0034243037     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Hotta T. Clonality in hematopoietic disorders. Int J Hematol. 1997;66:403-412.
2. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica. 1998;83:71-86.
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-20S8.